2seventy bio rose nearly 4% in pre-market trading! Its type A hemophilia project was acquired by Novo Nordisk
I'm PortAI, I can summarize articles.
2seventy bio announced the completion of an asset purchase agreement, where Novo Nordisk will acquire 2seventy bio's Type A Hemophilia project and the rights to gene editing technology. This transaction will help enhance 2seventy bio's commercialization and continued development of Abecma. As of the time of publication, 2seventy bio's pre-market trading on Thursday rose nearly 4%
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments